- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Low-Value Services: Their Impact and Challenges With Addressing Them
Jason Buxbaum, MHSA, project manager, V-BID Health; and Robert Dubois, MD, PhD, chief scientific officer, National Pharmaceutical Council, discuss low-value services, their financial impact, what states are doing to address them, and challenges with addressing them.
As conversations surrounding rising healthcare costs persist, the idea of addressing low-value services has caught the attention of health professionals nationwide. Value-Based Insurance Design (V-BID) Health’s Task Force on Low-Value Care has identified a top 5 list of low-value clinical services that can be targeted.
We spoke with Jason Buxbaum, MHSA, project manager, V-BID Health, about which 5 low-value services topped the list, the financial impact they have, and how states are attempting to address them.
Once low-value services are identified, healthcare professionals face another challenge: turning conversation into something actionable. We discussed the challenges with addressing these low-value services with Buxbaum and Robert Dubois, MD, PhD, chief scientific officer, National Pharmaceutical Council.
Listen above or through one of these podcast services:
iTunes: http://apple.co/2eYWTss
TuneIn: http://bit.ly/2gv7iwj
Stitcher: http://bit.ly/2gCqtFg
A Look at the Legal and Legislative Landscape Impacting Drug Costs for Patients
October 23rd 2024Kimberly Westrich, MA, of National Pharmaceutical Council, and Adam Colborn, JD, of AMCP, run through the current status of lawsuits and lawmaking at the federal and state levels related to pharmacy benefit managers and cost-shifting programs.
Read More
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
Dr John M. O'Brien Highlights Critical Role of Rebates in Employer Benefit Choices
August 5th 2024John M. O'Brien, PharmD, MPH, of the National Pharmaceutical Council, discusses his recent study, which sheds light on how important rebates are when choosing benefits for employers and who advises employers on these choices.
Read More
Prescription Rebate Guarantees: Employer Insights
July 19th 2024This study examined employers’ understanding of rebate guarantees, dependency upon rebate dollars, and the role that pharmaceutical rebates or employer benefits consultants play in their pharmacy benefits manager selection.
Read More
